Jbf Capital, Inc. Cellectis S.A. Transaction History

Jbf Capital, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Nov 13, 2018	SELL	$25.99 - $30.6 $1.56 Million - $1.84 Million	-60,000 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$27.78 - $38.53 $1.67 Million - $2.31 Million	60,000 New	60,000 $1.7 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Jbf Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Jbf Capital, Inc. with notifications on news.